Table 1.
Summary of emergent substitutions in selection experiments using CBMCsa
| Virusb | Subtype | Background substitution(s) | Drug(s) | Selected substitution(s) |
|---|---|---|---|---|
| 8336 | B | A98S, G190A | EFV | K101E |
| NL4-3 WT | B | None | EFV | K101E, V108I |
| 10583 | C | Y181C | EFV | K101E/K, V106M, Y181C |
| 8116 | B | A98S, G190A | DPV | K101E, Y181C |
| NL4- -Y181C | B | Y181C | DPV | K101E, V179I, Y181C |
| NL4-3-Y181C | B | Y181C | DPV-TDF | K101K/E, V108I/V, V179I/V, Y181C, H221Y |
| 10583 | C | Y181C | DPV-TDF | K101E/K, V108I/V, V179I/V, Y181C, H221Y |
| Mole 03c | C | None | ETR-FTC | K101E/K, E138E/K |
| Mole 03d | C | None | ETR-FTC | E138K, M184I. |
| Mole 03 | C | None | ETR-3TC | K101E, M184I |
a
Selection experiments were performed over 19 weeks. Abbreviations: 3TC, lamivudine; DPV, dapivirine; EFV, efavirenz; ETR, etravirine; FTC, emtricitabine; TDF, tenofovir disoproxil fumarate.
b
Viruses other than NL4-3 clones are clinical isolates from treatment-naive patients undergoing acute HIV-1 infection.
c
Viruses were genotyped at week 13.
d
Viruses were genotyped at week 19.